{"id":"in-vitro-sensitivity-directed-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Bone marrow suppression"},{"rate":null,"effect":"Infection"}]},"_chembl":{"chemblId":"CHEMBL5715933","moleculeType":null,"molecularWeight":"612.41"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"This approach involves testing various chemotherapeutic drugs against a patient's tumor cells in vitro to determine which drugs are most effective at killing the cancer cells. The results guide the selection of the most appropriate chemotherapy regimen for the patient.","oneSentence":"In vitro sensitivity-directed chemotherapy selects chemotherapeutic agents based on the sensitivity of tumor cells tested in a laboratory setting.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:46.251Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pediatric solid tumors, including sarcomas and neuroblastoma"}]},"trialDetails":[{"nctId":"NCT02551718","phase":"NA","title":"High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia","status":"COMPLETED","sponsor":"University of Washington","startDate":"2015-09-11","conditions":"Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia","enrollment":34},{"nctId":"NCT00003214","phase":"PHASE3","title":"Chemosensitivity Testing to Assign Treatment for Patients With Stage III or Stage IV Ovarian Cancer","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"1996-07","conditions":"Ovarian Cancer","enrollment":300},{"nctId":"NCT01395628","phase":"","title":"Cell Samples From Patients With Leukemia","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2011-07","conditions":"Leukemia","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"in vitro sensitivity-directed chemotherapy","genericName":"in vitro sensitivity-directed chemotherapy","companyName":"Children's Oncology Group","companyId":"children-s-oncology-group","modality":"Small molecule","firstApprovalDate":"","aiSummary":"In vitro sensitivity-directed chemotherapy selects chemotherapeutic agents based on the sensitivity of tumor cells tested in a laboratory setting. Used for Pediatric solid tumors, including sarcomas and neuroblastoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}